Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALTO-202
- Development stage
- Unknown
- Lead developer
- Alto Neuroscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALTO-202 is an orally bioavailable small molecule drug in development by Alto Neuroscience for the treatment of major depressive disorder (MDD). It acts as a negative allosteric modulator of the GluN2B subunit of the NMDA receptor, building on the antidepressant effects observed with NMDA receptor antagonists like ketamine but without exhibiting common dissociative adverse effects. The drug has demonstrated a favorable safety profile across various clinical populations and is currently in Phase 2 clinical trials for MDD. It was also previously under development for post-traumatic stress disorder (PTSD)[1][2][3][5].
02
Targets
GRIN2B (N-methyl-D-aspartate Receptor Subunit Combination: NR1a/NR2B)
Beyond the preview
Go deeper on ALTO-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALTO-202.